Kendall Capital Management Acquires Shares of 5,881 United Therapeutics Corporation $UTHR

Kendall Capital Management acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, Holdings Channel.com reports. The firm acquired 5,881 shares of the biotechnology company’s stock, valued at approximately $3,187,000.

Several other large investors have also made changes to their positions in UTHR. Hudson Portfolio Management LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $740,000. Daiichi Life Insurance Co. Ltd. acquired a new stake in United Therapeutics in the 2nd quarter valued at $4,485,000. Commerce Bank purchased a new stake in United Therapeutics in the 2nd quarter worth $784,000. Northwestern Mutual Wealth Management Co. purchased a new stake in United Therapeutics in the 2nd quarter worth $341,000. Finally, Evolve Private Wealth LLC acquired a new position in United Therapeutics during the second quarter worth $6,900,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on UTHR shares. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. raised their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Stock Down 1.5%

Shares of UTHR opened at $513.12 on Friday. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The firm’s fifty day moving average is $533.08 and its two-hundred day moving average is $537.36. The stock has a market cap of $22.01 billion, a PE ratio of 18.36, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.41 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,185,729.06. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 442,575 shares of company stock worth $239,326,330 over the last 90 days. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.